CYT - Cyteir Therapeutics GAAP EPS of -$0.31 beats by $0.08
- Cyteir Therapeutics press release ( NASDAQ: CYT ): Q3 GAAP EPS of -$0.31 beats by $0.08 .
-
Cash and cash equivalents as of September 30, 2022 were $153.9 million. Cash and cash equivalents are expected to fund planned operations into the second half of 2024.
-
Research and development (R&D) expenses: R&D expenses were $8.3 million in third quarter of 2022 versus $8.2 million for the same period in 2021.
-
General and administrative (G&A) expenses: G&A expenses were $3.5 million for the third quarter of each 2022 and 2021.
For further details see:
Cyteir Therapeutics GAAP EPS of -$0.31 beats by $0.08